The grant will be used to hire an Innovation Associate who will work on the implementation of innovative (bio)analytical techniques with high spatial resolution to better understand the microdistribution and local behaviour of CriPec® nanomedicines within the tumour microenvironment (TME)....
Under the terms of the agreement, Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac® vaccine candidate based on the receptor-binding domain of the SARS-CoV-2 spike protein. In addition, Cristal Therapeutics will provide its powerful copper-free click chemistry reagent, CliCr®,...
Dr Cautreels succeeds Simon Sturge, who steps down to focus on his new role as CEO at Kymab. In addition, Andre Verwei is appointed as Chief Financial Officer (CFO) with immediate effect....
Dr. Mescheder joins Cristal Therapeutics from Lanthio Pharma, a Dutch company and part of MorphoSys AG, where he served as Chief Medical and Development Officer. He brings over 25 years of clinical development and regulatory experience gained from senior leadership roles that have included Vice...
The new funding will be used to continue and accelerate the clinical development of Cristal Therapeutics’ lead candidate CriPec® docetaxel, by executing a clinical phase Ib trial, building the momentum for a clinical phase II trial starting later this year....